Emerging Molecular Insights and Targeted Therapeutics in Colorectal Cancer: From Emerging Approaches to Personalized Medicine.

Colorectal cancer (CRC) is the third most prevalent malignancy and the second leading cause of cancer-related deaths globally. Recent research emphasizes personalized medicine as it tailors treatment to the patient’s tumor genetics, improving therapeutic response and reducing toxicity. It improves illness management by enabling precise targeted immunotherapies, better treatment outcomes, and early identification and risk assessment. On a molecular level, CRC is driven by a spectrum of genetic alterations involving oncogenes, tumor suppressor genes, and genes responsible for maintaining genomic integrity. Based on the nature and origin of these mutations, CRC is typically classified into sporadic, familial, and hereditary subtypes. The disease is underpinned by three principal molecular mechanisms: chromosomal instability (CIN), microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP). KRAS, BRAF, PIK3CA, PTEN, SMAD2, SMAD4, and c-MYC are oncogenic and tumor suppressor genes that are frequently altered in CRC. These genes affect tumor biology and clinical outcomes, making them useful biomarkers. Besides protein-coding gene changes, dysregulation of non-coding RNAs (ncRNAs) has been linked to colorectal carcinogenesis, presenting promising early detection and prognostication methods. Therapeutically, advances have included the integration of monoclonal antibodies targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) pathways. More recently, the development of targeted agents, such as tyrosine kinase inhibitors and next-generation biologics, aims to optimize therapeutic efficacy while reducing systemic toxicity. This review focuses on the Targeted and personalized CRC treatment, highlighting low-toxicity regimens, significant clinical trial outcomes, ongoing challenges, and potential future directions in personalized medicine.